The changing epidemiology of the ageing thalassaemia populations: A position statement of the Thalassaemia International Federation.
Thalassaemia
ageing
comorbidities
survival
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
11
01
2020
revised:
15
03
2020
accepted:
17
03
2020
pubmed:
22
3
2020
medline:
22
6
2021
entrez:
22
3
2020
Statut:
ppublish
Résumé
Therapeutic advances in β-thalassaemia have gradually lead to a significant improvement in prognosis over the past few decades. As a result, patients living in areas where disease-specific programmes offering access to modern therapy are in place experience a new era of prolonged survival that tends to reach that of the normal population. This ageing thalassaemia population, however, faces a new spectrum of comorbidities resulting from increasing age that may jeopardise the advances in prognosis provided by current therapy and thus poses new challenges in diagnosis, monitoring and treatment. In this position paper of the Thalassaemia International Federation, we review the changing epidemiology and clinical spectrum of patients with β-thalassaemia and propose actions to be undertaken in order to address the emerging spectrum of comorbidities resulting from ageing.
Types de publication
Historical Article
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
16-23Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187-1193.
Weidlich D, Kefalas P, Guest JF. Healthcare costs and outcomes of managing β-thalassemia major over 50 years in the United Kingdom. Transfusion. 2016;56(5):1038-1045.
Voskaridou E, Kattamis A, Fragodimitri C, et al. Papassotiriou I; Greek Haemoglobinopathies Study Group. National registry of hemoglobinopathies in Greece: updated demographics, current trends in affected births, and causes of mortality. Ann Hematol. 2019;98(1):55-66.
Engle MA, Erlandson M, Smith CH. Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. Circulation. 1964;30:698-705.
Ladis V, Chouliaras G, Berdoukas V, et al. Survival in a large cohort of Greek patients with transfusion-dependent beta thalassaemia and mortality ratios compared to the general population. Eur J Haematol. 2011;86(4):332-338.
Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet. 1989;2(8653):27-30.
Kremastinos D, Farmakis D. Iron overload cardiomyopathy in clinical practice. Circulation. 2011;124:2253-2263.
Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10:42.
Pinto VM, Poggi M, Russo R, Giusti A, Forni GL. Management of the aging beta-thalassemia transfusion-dependent population - The Italian experience. Blood Rev. 2019;38:100594.
Motta I, Mancarella M, Marcon A, Vicenzi M, Cappellini MD. Management of age-associated medical complications in patients with β-thalassemia. Expert Rev Hematol. 2020;13:85-94.
Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Jordan LC, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019;139(10):e56-e528.
Koohi F, Kazemi T, Miri-Moghaddam E. Cardiac complications and iron overload in beta thalassemia major patients-a systematic review and meta-analysis. Ann Hematol. 2019;98(6):1323-1331.
Pepe A, Gamberini MR, Missere M, et al. Meloni A; Working Group of Gender Medicine of Italian Society of Cardiology. Gender differences in the development of cardiac complications: a multicentre study in a large cohort of thalassaemia major patients to optimize the timing of cardiac follow-up. Br J Haematol. 2018;180(6):879-888.
Aessopos A, Farmakis D, Karagiorga M, et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood. 2001;97(11):3411-3416.
Aessopos A, Farmakis D, Loukopoulos D. Elastic tissue abnormalities resembling pseudoxanthoma elasticum in beta thalassemia and the sickling syndromes. Blood. 2002;99(1):30-35.
Farmakis D, Aessopos A. Pulmonary hypertension associated with hemoglobinopathies: prevalent but overlooked. Circulation. 2011;123(11):1227-1232.
Aessopos A, Farmakis D, Tsironi M, et al. Endothelial function and arterial stiffness in sickle-thalassemia patients. Atherosclerosis. 2007;191(2):427-432.
Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol. 2014;28(5):753-770.
Moukhadder HM, Halawi R, Cappellini MD, Taher AT. Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: A comprehensive review. Cancer. 2017;123(5):751-758.
Finianos A, Matar CF, Taher A. Hepatocellular carcinoma in β-thalassemia patients: review of the literature with molecular insight into liver carcinogenesis. Int J Mol Sci. 2018;19(12).
Marsella M, Ricchi P. Thalassemia and hepatocellular carcinoma: links and risks. J Blood Med. 2019;10:323-334.
Ahmad N, Adams DM, Wang J, Prakash R, Karim NA. Hepatic epithelioid hemangioendothelioma in a patient with hemochromatosis. J Natl Compr Canc Netw. 2014;12:1203-1207.
Poggi M, Sorrentino F, Pascucci C, et al. Malignancies in β-thalassemia patients: first description of two cases of thyroid cancer and review of the literature. Hemoglobin. 2011;35(4):439-446.
Joosten E, Meeuwissen J, Vandewinckele H, Hiele M. Iron status and colorectal cancer in symptomatic elderly patients. Am J Med. 2008;121(12):1072-1077.
Borgna-Pignatti C, Vergine G, Lombardo T, et al. Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol. 2004;124(1):114-117.
Zanella S, Garani MC, Borgna-Pignatti C. Malignancies and thalassemia: a review of the literature. Ann N Y Acad Sci. 2016;1368(1):140-148.
He LN, Chen W, Yang Y, et al. Elevated prevalence of abnormal glucose metabolism and other endocrine disorders in patients with β-Thalassemia major: a meta-analysis. Biomed Res Int. 2019 Apr;18(2019):6573497.
De Sanctis V, Kattamis C, Canatan D, et al. β-Thalassemia distribution in the old World: an ancient disease seen from a historical standpoint. Mediterr J Hematol Infect Dis. 2017;9(1):e2017018.
De Sanctis V, Soliman AT, Canatan D, et al. An ICET-A survey on occult and emerging endocrine complications in patients with β-thalassemia major: Conclusions and recommendations. Acta Biomed. 2019;89(4):481-489.
Akıncı B, Yaşar AŞ, Özdemir Karadaş N, et al. Fertility in patients with thalassemia and outcome of pregnancies: a Turkish experience. Turk J Haematol. 2019;36(4):274-277.
De Sanctis V, Soliman AT, Yassin MA, et al., Kattamis C. Hypogonadism in male thalassemia major patients: pathophysiology, diagnosis and treatment. Acta Biomed. 2018;89(2-S);6-15.
Taher A, Isma’eel H, Mehio G, Bignamini D, Kattamis A, Rachmilewitz EA, , et al. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost. 2006;96:488-491.
Haghpanah S, Karimi M. Cerebral thrombosis in patients with β-thalassemia: a systematic review. Blood Coagul Fibrinolysis. 2012;23(3):212-217.
Abosdera MM, Almasry AE, Abdel-Moneim ES. Coagulation defects in thalassemic patients. Pediatr Neonatol. 2017;58(5):421-424.
Aessopos A, Farmakis D, Karagiorga M, Rombos I, Loucopoulos D. Pseudoxanthoma elasticum lesions and cardiac complications as contributing factors for strokes in beta-thalassemia patients. Stroke. 1997 Dec;28(12):2421-2424.
Sleiman J, Tarhini A, Bou-Fakhredin R, Saliba AN, Cappellini MD, Taher AT. Non-transfusion-dependent thalassemia: an update on complications and management. Int J Mol Sci. 2018;19(1).
Ahmadzadeh A, Jalali A, Assar S, et al. Renal tubular dysfunction in pediatric patients with beta-thalassemia major. Saudi J Kidney Dis Transpl. 2011;22:497-500.
Demosthenous C, Vlachaki E, Apostolou C, et al. Beta-thalassemia: renal complications and mechanisms: a narrative review. Hematology. 2019;24(1):426-438.
Al-Khabori M, Bhandari S, Al-Huneini M, Al-Farsi K, Panjwani V, Daar S. Side effects of Deferasirox iron chelation in patients with beta thalassemia major or intermedia. Oman Med J. 2013;28(2):121-124.
Mokhtar GM, Gadallah M, El Sherif NH, et al. Morbidities and mortality in transfusion dependent beta-thalassemia patients (single-center experience). Pediatr Hematol Oncol. 2013;30:93-103.
Chen YG, Lin TY, Chen HJ, Dai MS, Ho CL, Kao CH. Thalassemia and risk of dementia: a nationwide population-based retrospective cohort study. Eur J Intern Med. 2015;26(7):554-559.
Franchini M, Forni GL, Marano G, et al. Red blood cell alloimmunisation in transfusion-dependent thalassaemia: a systematic review. Blood Transfus. 2019;17(1):4-15.
Noureldine MHA, Taher AT, Haydar AA, Berjawi A, Khamashta MA, Uthman I. Rheumatological complications of beta-thalassaemia: an overview. Rheumatology (Oxford). 2018;57(1):19-27.
De Sanctis V, Soliman AT, Elsefdy H, et al. Bone disease in β thalassemia patients: past, present and future perspectives. Metabolism. 2018;80:66-79.
Piga A. Impact of bone disease and pain in thalassemia. Hematology Am Soc Hematol Educ Program. 2017;2017(1):272-277.
Vogiatzi MG, Macklin EA, Fung EB, et al., Giardina PJ. Bone disease in thalassemia: a frequent and still unresolved problem. J Bone Miner Res. 2009;24(3):543-557.
Trachtenberg F, Foote D, Martin M, et al. Pain as an emergent issue in thalassemia. Am J Hematol. 2010;85(5):367-370.
Lal A. Assessment and treatment of pain in thalassemia. Ann N Y Acad Sci. 2016;1368(1):65-72.
Haines D, Martin M, Carson S, et al., VichinskyE; Thalassemia Clinical Research Network. Pain in thalassaemia: the effects of age on pain frequency and severity. Br J Haematol. 2013;160(5):680-687.
Oliveros O, Trachtenberg F, Haines D, et al., VichinskyE; Thalassemia Clinical Research Network. Pain over time and its effects on life in thalassemia. Am J Hematol. 2013;88(11):939-943.
Green ST, Martin MB, Haines D, et al. Variance of pain prevalence and associated severity during the transfusion cycle of adult thalassaemia patients. Br J Haematol. 2014;166(5):797-800.
Pliakou XI, Koutsouka FP, Damigos D, Bourantas KL, Briasoulis EC, Voulgari PV. Rheumatoid arthritis in patients with hemoglobinopathies. Rheumatol Int. 2012;32(9):2889-2892.
Liaska A, Petrou P, Georgakopoulos CD, et al. β-Thalassemia and ocular implications: a systematic review. BMC Ophthalmol. 2016;16:102.
Jafari R, Heydarian S, Karami H, et al. Ocular abnormalities in multi-transfused beta-thalassemia patients. Indian J Ophthalmol. 2015;63:710-715.
Khan MA, Khan MA, Seedat AM, et al. Sensorineural Hearing Loss and Its Relationship with Duration of Chelation Among Major β-Thalassemia Patients. Cureus. 2019;11(8):e5465.
Kassebaum NJ, Bernabé E, Dahiya M, Bhandari B, Murray CJ, Marcenes W. Global burden of severe periodontitis in 1990-2010: a systematic review and meta-regression. J Dent Res. 2014;93(11):1045-1053.
Tonetti MS, Jepsen S, Jin L, Otomo-Corgel J. Impact of the global burden of periodontal diseases on health, nutrition and wellbeing of mankind: A call for global action. J Clin Periodontol. 2017;44(5):456-462.
Akcalı A, Yıldız MS, Akcalı Z, Huck O, Friedmann A. Periodontal condition of patients with Thalassemia Major: A systematic review and meta-analysis. Arch Oral Biol. 2019;102:113-121.
Caocci G, Orofino MG, Vacca A, et al. Long-term survival of beta thalassemia major patients treated with hematopoietic stem cell transplantation compared with survival with conventional treatment. Am J Hematol. 2017;92(12):1303-1310.
https://www.who.int/sdg.